Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: In October 2017, we entered into certain agreements with Patheon related to the increase of our long-term production capacity for ARIKAYCE. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated commercial needs. Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE. Patheon's supply obligations will commence once certain technology transfer and construction services are completed. Our manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either we or Patheon have given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party’s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The aggregate investment to increase our long-term production capacity, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million. Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) In 2004 and 2009, we entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics, Inc. Assistant:

  2. Assistant

    Positive: In October 2017, we formalized agreements with Patheon to enhance our long-term production capacity for ARIKAYCE. These agreements stipulate that Patheon will produce and supply ARIKAYCE according to our projected commercial requirements. We are responsible for supplying Patheon with the necessary raw materials, including active pharmaceutical ingredients and certain fixed assets essential for manufacturing ARIKAYCE. Patheon will begin fulfilling its supply obligations once the required technology transfer and construction tasks are concluded. Our agreement with Patheon for manufacturing and supply will continue for an initial fixed period and will then automatically renew unless either party issues a written termination notice. The technology transfer agreement concludes when both parties concur on the completion of the technology transfer services. These agreements might also be nullified under other circumstances, such as if one party commits an unresolved major breach or becomes insolvent. Such early termination provisions might influence the financial obligations of the involved parties. The total projected investment to boost our long-term production capacity, including agreements with Patheon and related arrangements for raw materials and fixed assets with third parties, is estimated to be around $60 million. In 2004 and 2009, we signed research funding agreements with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT).

    Negative: In October 2017, we decided against entering into agreements with Patheon, which would have boosted our long-term production capacity for ARIKAYCE. The non-existent agreements would have meant Patheon would neither manufacture nor supply ARIKAYCE for our commercial needs. We are not required to provide Patheon with any raw materials or fixed assets. As there are no obligations, Patheon doesn’t need to wait for technology transfers or construction services to start. There is no ongoing relationship with Patheon for manufacturing and supply, and no renewal terms apply. The anticipated technology transfer services will not occur, and such agreements could not be terminated for any causes, including breaches or insolvency. Early termination clauses are irrelevant, as monetary involvement is nonexistent. The conjectural investment to enhance our production capacity, had those agreements existed, including hypothetical purchase orders for materials, exceeds $60 million. We did not enter into research funding agreements with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) in 2004 and 2009.